Cytokeratin 5 (KRT5) antibody

Antigen: Cytokeratin 5 (KRT5)

Synonyms: KRT79, CK5, KRT5, K5, Tfip8, Krt2-5, AW146334, 3300001P10Rik, DDD, EBS2, KRT5A

Clonality: Monoclonal (XM26)

Host: Mouse

Reactivity: Human

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Catalog no.: ABIN98114

Additional Information

Alternative name: Cytokeratin 5

Immunogen: BALB/C mice were injected with prokaryotic recombinant protein corresponding to 103 amino acid portion of C-terminal region of the human cytokeratin 5 molecule.

Format: Supernatant

Isotype: IgG1 kappa  (Matching secondary antibodies)

Clone: XM26

Specificity: This antibody reacts with cytokeratin 5 intermediate filament protein. Basal cells of human epidermis express acidic cytokeratin 14 and basic cytokeratin 5. Cytokeratin 5 is a 58 kD protein, which is closely related to cytokeratin 6. Cytokeratin 5 and 6 are expressed in basal cell epithelioma, basal cells of prostate, urothelium, vagina, squamous cell carcinomas of skin, tongue, epiglottis and rectal-anal region. Cytokeratin 5 can be useful in the distinction of mesotheliomas from most adenocarcinomas.

Application Details

Application Notes: Titer/Working Dilution: This antibody may be diluted to a titer of 1:50-1:75 in an ABC method. However, depending on the staining conditions employed, we suggest that final dilution should be determined by the user. Staining Protocol: We suggest an incubation period of 30 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the end user. Formalin fixed paraffin embedded tissue sections require high temperature antigen unmasking with 10 mM citrate buffer, pH 6.0 prior to immunostaining. Positive Control: Skin. Cellular localization: Cytoplasmic

Concentration: 100ug/ml approximately

Buffer: This antibody is supplied as culture supernatant containing sodium azide as preservative.

Storage: Store the antibody at 2-8o c. Do not use it beyond the expiration date stated on the label.

Research Area: Extracellular Matrix

Restrictions: For Research Use. CE-certified for In Vitro Diagnostics (IVD) Use in the European Union

Publications

Publications: Irvine, McKenna, Jenkinson et al.: "A mutation in the V1 domain of keratin 5 causes epidermolysis bullosa simplex with mottled pigmentation." in: The Journal of investigative dermatology, Vol. 108, Issue 5, pp. 809-10, 1997 (PubMed).

Whittock, Eady, McGrath: "Genomic organization and amplification of the human epidermal type II keratin genes K1 and K5." in: Biochemical and biophysical research communications, Vol. 274, Issue 1, pp. 149-52, 2000 (PubMed).

Chamcheu, Loriue, Akgul et al.: "Characterization of immortalized human epidermolysis bullosa simplex (KRT5) cell lines: trimethylamine N-oxide protects the keratin cytoskeleton against disruptive stress condition." in: Journal of dermatological science, Vol. 53, Issue 3, pp. 198-206, 2009 (PubMed).

Akguel, Zigrino, Frith et al.: "Proteomic analysis reveals the actin cytoskeleton as cellular target for the human papillomavirus type 8." in: Virology, Vol. 386, Issue 1, pp. 1-5, 2009 (PubMed).